Biotech Analyst Watsek, along with Dr. Paolo Strati, Ast Professor, Department of Lymphoma/Myeloma, The University of Texas, discuss Evorpacept in combination with Rituxan-based regimens for iNHL on an Analyst/Industry conference call to be held on April 11 at 2:30 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
- ALX Oncology reports clinical data from Phase 1/2 trial of evorpacept
- ALX Oncology price target raised to $20 from $17.50 at H.C. Wainwright
- ALX Oncology price target raised to $21 from $11 at Piper Sandler
- ALX Oncology downgraded to Hold from Buy at Stifel
